The introduction of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable buzz within the healthcare community. This novel dual GIP and GLP-1 agonist medication appears to offer notable improvements in weight loss compared to current therapies. Preliminary clinical studies have demonst